What follow-up tests do I need after Ovarian Cancer treatment ends

Follow-Up Testing After Ovarian Cancer Treatment

Great question—understanding what monitoring looks like after treatment is an important part of your care plan. Let me walk you through what's typically recommended.

Standard Follow-Up Schedule

According to the NCCN Guidelines for Ovarian Cancer, after you complete your primary treatment (surgery and/or chemotherapy), your follow-up typically includes:

For the first 2 years:

• Visits every 2-4 months with your oncology team

Years 2-5:

• Visits every 3-6 months

After 5 years:

• Annual visits

What Tests Are Typically Included

Physical Examination

• Regular pelvic exams as clinically indicated
• General physical exam to assess overall health

Imaging Studies (as clinically indicated)

Your doctor may order imaging such as:

• CT scans (chest/abdomen/pelvis with contrast)
• MRI (particularly if you have kidney issues that make CT contrast problematic)
• PET/CT scans (if there's concern about recurrence)
• Pelvic ultrasound

These aren't done automatically at every visit—your oncologist orders them based on your specific situation and any symptoms you develop.

Blood Work

• Complete blood count (CBC) — checks your red and white blood cells and platelets
• Chemistry panel — evaluates kidney and liver function
• CA-125 tumor marker (if it was elevated at diagnosis)

Important Context About CA-125 Monitoring

Here's something important to understand: CA-125 is optional for surveillance, according to the NCCN Guidelines and the Society of Gynecologic Oncology (SGO).

Why? Research shows that:

• Treating cancer early based on a rising CA-125 (when you have no symptoms) doesn't improve survival
• It can actually decrease quality of life by creating anxiety and leading to unnecessary treatments

The recommendation: Discuss with your oncologist whether CA-125 monitoring makes sense for YOUR situation. Some patients prefer monitoring it; others prefer to focus on symptoms and imaging only. This is a shared decision between you and your care team.

What to Watch For Between Visits

The NCCN Guidelines recommend you be educated about signs and symptoms that might suggest recurrence:

• Pelvic pain or pressure
• Bloating or abdominal distension
• Early satiety (feeling full quickly when eating)
• Bowel obstruction symptoms
• Unexplained weight loss
• Persistent fatigue

If you experience any of these, contact your oncologist rather than waiting for your next scheduled visit.

Molecular Testing at Recurrence

If recurrence is suspected, your doctor may recommend additional molecular testing on tumor tissue to identify:

• BRCA1/2 status (if not done previously)
• HRD status (homologous recombination deficiency)
• Other biomarkers that might guide treatment options

This testing informs what treatment options might be most effective if recurrence occurs.

Genetic Counseling

If you haven't had genetic risk evaluation and testing, the NCCN Guidelines recommend discussing this with your care team, as it can inform:

• Your own surveillance
• Screening recommendations for family members
• Treatment options if recurrence occurs

Long-Term Wellness Care

Beyond cancer surveillance, the NCCN Guidelines recommend:

• General preventive health care
• Management of treatment side effects (like bone health if you had chemotherapy)
• Mental health support and survivorship resources
• Lifestyle counseling

---

Questions to Ask Your Oncologist

Since every patient's situation is different, here are specific questions to personalize your follow-up plan:

1. "What is MY specific follow-up schedule, and does it differ from standard recommendations based on my stage or other factors?"

2. "Should we monitor CA-125, or would you recommend focusing on symptoms and imaging instead?"

3. "What imaging will you order, and how often? What triggers additional imaging between visits?"

4. "What symptoms should I report immediately versus waiting for my next appointment?"

5. "Do I need any genetic testing or counseling, and if so, when should that happen?"

6. "Are there any survivorship resources or support programs you recommend?"

---

Key Sources

According to the NCCN Guidelines Version 3.2025 for Ovarian Cancer, monitoring recommendations are individualized based on your stage, treatment response, and specific risk factors. The guidelines emphasize that while surveillance is important, the goal is to balance cancer monitoring with quality of life.

The Society of Gynecologic Oncology (SGO) position statement notes that CA-125 surveillance is optional and should be a shared decision with your care team.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about your specific follow-up plan.